Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.35 |
| ▸ | WNT3A | P56704 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48860 | 0.90 | SIGMAR1 (0.56) | SIGMAR1CYP2A6OPRM1OPRK1CTNNB1 | |
| SCHEMBL48003 | 0.90 | SIGMAR1 (0.64) | SIGMAR1CYP2A6OPRM1OPRK1CTNNB1 | |
| SCHEMBL14492351 | 0.88 | SIGMAR1 (0.54) | SIGMAR1CYP2A6OPRM1OPRK1CTNNB1 | |
| SCHEMBL48172 | 0.85 | SIGMAR1 (0.51) | SIGMAR1CYP2A6OPRM1OPRK1CTNNB1 | |
| SCHEMBL48233 | 0.85 | SIGMAR1 (0.51) | SIGMAR1CYP2A6OPRM1OPRK1CTNNB1 | |
| SCHEMBL48261 | 0.84 | SIGMAR1 (0.50) | SIGMAR1CYP2A6OPRM1OPRK1CTNNB1 | |
| SCHEMBL48155 | 0.84 | SIGMAR1 (0.51) | SIGMAR1CYP2A6OPRM1OPRK1CTNNB1 | |
| SCHEMBL52456 | 0.84 | SIGMAR1 (0.52) | SIGMAR1CYP2A6OPRM1OPRK1ROCK2 | |
| SCHEMBL48246 | 0.84 | SIGMAR1 (0.50) | SIGMAR1CYP2A6OPRM1OPRK1CTNNB1 | |
| SCHEMBL47947 | 0.83 | SIGMAR1 (0.49) | SIGMAR1CYP2A6OPRM1OPRK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348022-B1 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salts thereof | TOYAMA CHEMICAL CO LTD (JP) | 2013-01-09 | — | — | EP | claimed |
| US-8273902-B2 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-25 | — | — | US | claimed |
| EP-2348022-A1 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salts thereof | Toyama Chemical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | claimed |
| US-20110098484-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)- ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | claimed |
| EP-2210884-A2 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propionic acid and 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol as well as salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-28 | — | — | EP | claimed |
| US-20090069576-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)-ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD (JP) | 2009-03-12 | — | — | US | claimed |
| EP-1864978-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)- ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | claimed |
| EP-3705121-B1 | EMOPAMIL BINDING PROTEIN BINDING AGENT AND USE THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-11548878-B2 | Emopamil binding protein binding agent and use thereof | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20210198245-A1 | EMOPAMIL BINDING PROTEIN BINDING AGENT AND USE THEREOF | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3705121-A1 | EMOPAMIL BINDING PROTEIN BINDING AGENT AND USE THEREOF | FUJIFILM Toyama Chemical Co., Ltd. (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-20200206187-A1 | SCREENING PLATFORM TO IDENTIFY THERAPEUTIC DRUGS OR AGENTS FOR TREATMENT OF ALZHEIMER'S DISEASE | TANZI RUDOLPH E (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111163770-A | Screening platform for identifying therapeutic drugs or agents for treating alzheimer's disease | 综合医院公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1614419-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069576-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)-ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | PMP22, ACOX1, PAOX | SIGMAR1 1914/4885CYP2A6 1393/4885OPRM1 557/4885 |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | RB1, ALDH1A2, NR2E3 | SIGMAR1 2529/4885CYP2A6 3200/4885OPRM1 3166/4885 |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | SIGMAR1 1934/4885CYP2A6 3512/4885OPRM1 1485/4885 |
| US-20110098484-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)- ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | PMP22, ACOX1, PAOX | SIGMAR1 1914/4885CYP2A6 1393/4885OPRM1 557/4885 |
| US-20210198245-A1 | EMOPAMIL BINDING PROTEIN BINDING AGENT AND USE THEREOF | EBPL, SERPINA6, CRHBP | SIGMAR1 3215/4885CYP2A6 3607/4885OPRM1 1136/4885 |
| US-11548878-B2 | Emopamil binding protein binding agent and use thereof | EBPL, SERPINA6, CRHBP | SIGMAR1 3215/4885CYP2A6 3607/4885OPRM1 1136/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | SIGMAR1 1934/4885CYP2A6 3512/4885OPRM1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.